nach oben

Wiener klinische Wochenschrift Education

Erschienen in:

01.06.2015

Diagnose und Therapie der erworbenen Aplastischen Anämie

verfasst von: Ao. Univ. Prof. Dr. Wolfgang Füreder

Erschienen in: Wiener klinische Wochenschrift Education | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten

Auszug

P. Balcke, St. Pölten …

Vorheriger Artikel Direkte orale Antikoagulantien: Welche Patienten eignen sich zur Behandlung mit diesen Substanzen?

Nächster Artikel Gefäßkatheter-assoziierte Infektionen

Nur mit Berechtigung zugänglich

Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.PubMedCentralPubMedCrossRef

Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70.PubMedCrossRef

Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120:1185–96.PubMedCentralPubMedCrossRef

Gupta V, Brooker C, Tooze JA, Yi QL, Sage D, Turner D, Kangasabapathy P, Marsh JC. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. 2006;134: 95–9.PubMedCrossRef

Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–5.PubMed

Kojima S, Nakao S, Tomonaga M, Hows J, Marsh J, Gerard S, Bacigalupo A, Mizoguchi H. Consensus conference on the treatment of aplastic anemia. Int J Hematol. 2000;72:118–23.PubMed

Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, Oneto R, Passweg JR. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94:1312–5.PubMedCentralPubMedCrossRef

Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.PubMedCrossRef

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.PubMedCentralPubMedCrossRef

10.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119:345–54.PubMedCentralPubMedCrossRef

11.

Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117:4434–41.PubMedCrossRef

12.

Füreder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011;52:1435–45.PubMedCrossRef

13.

Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S, Halter J, Gupta V, Bacigalupo A, Sociè G, Tichelli A, Schrezenmeier H, Marsh J, Passweg J, Rotoli B. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148:791–6.PubMedCrossRef

14.

Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.PubMedCentralPubMedCrossRef

15.

Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remissionin severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491–4.PubMed

16.

Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–42.PubMedCrossRef

17.

Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant. 2013;48:198–200.PubMedCrossRef

Titel: Diagnose und Therapie der erworbenen Aplastischen Anämie
verfasst von: Ao. Univ. Prof. Dr. Wolfgang Füreder
Publikationsdatum: 01.06.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift Education / Ausgabe 1-2/2015
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765
DOI: https://doi.org/10.1007/s11812-015-0068-3

Springer Medizin Österreich

Diagnose und Therapie der erworbenen Aplastischen Anämie

Auszug

Weitere Artikel der Ausgabe 1-2/2015

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten